Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

17/86 subjects), with no

differences among the active drug group and the placebo group

* Plasma levels of larazotide acetate were below the limits of

quantification (0.5 ng/ml) in all groups at days 0, 7 and 14

"Although the primary study outcome was not statistically significant, a great deal was learned about the potential effects of larazotide acetate and the secondary outcome data is very positive. Further, important new information was gained about the best way to run a celiac disease clinical trial. This trial marks the beginning of a new era in celiac therapeutics where modalities beyond diet alone have the ability to improve the lives of our patients," stated Daniel Leffler, MD a gastroenterologist from Beth Israel Deaconess Medical Center.

"We are very encouraged by the clear trend in the reduction of intestinal permeability and the signs and symptoms of gluten exposure in patients with celiac disease. We have applied the knowledge gained in this Phase IIa clinical trial to a larger Phase IIb gluten challenge study which is currently ongoing. In addition, we have recently initiated a clinical trial in 106 active celiac disease patients. Alba is committed to developing and studying new treatment options for patients with celiac disease," stated Dr. Francisco Leon, Head of Clinical Research and Development at Alba. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Celiac Disease

Celiac disease is a lifelong T-cell mediated auto-immune disorder, which occurs in individuals who are genetically susceptible and is characterized by small intestinal inflammation, injury and intolerance to gluten. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. People with CD cannot tole
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Today, in final recognition of the Centers for Disease ... Contacts is sharing how to keep lens cases clean.  ... do not properly care for their lens cases are ... Most contact lens wearers understand the importance of ... is sometimes overlooked.  When proper steps to clean a ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Latanoprost ... Developed by Pharmacia & Upjohn in 1995, ... effectively reduces intraocular pressure. As the first pressure- ... trade name of Xalatan) entered China ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... March 25, 2007 /PRNewswire/ -- Once-daily,dosing with ... antagonist, was associated with improvements,in signs and ... hospitalized patients receiving conventional care, without an,adverse ... These,data are from the short- and long-term ...
... BETHESDA, Md., March 26, 2007--Having a build-up of ... heart attacks and,death from heart disease in multiple ... Study of Atherosclerosis (MESA),funded by the National Heart, ... Health. Previous studies have shown that,increased coronary artery ...
Cached Medicine Technology:Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7Calcium Plaque Build-up in the Arteries Leads to Coronary Heart,Disease in Multi-Ethnic Groups 2
(Date:8/29/2015)... Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Pro X . Each preset contains 15 seconds of unique footage that users can ... that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced today ... and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. ... (VHS) in the United States District Court for the Southern District of Texas ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... DALLAS, Nov. 20 Crdentia Corp. (OTC Bulletin,Board: ... the,promotion of Ms. Penny Kirsch to Vice President ... Human Resources Manager,for Crdentia and will continue to ... Kirsch will be responsible for all human resources ...
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials company ... delivery products, today,announced that President and CEO Robert P. ... Annual Healthcare Conference at the Palace,Hotel in New York ... EST. Lazard Capital Markets will host a web ...
... System Included in Molecular Imaging Zone, FORT ... (OTC Bulletin Board: IMDS) a pioneer in laser,optical ... will,feature breast cancer cases imaged with optical computed ... November 25 - 28. A CT,Laser Mammography (CTLM(R)) ...
... today the pricing of its public offering of 1,466,400 ... $3.50 per share. Uroplasty,has granted the underwriters a 30-day ... common stock at the offering price to cover,over-allotments. The ... to expand its sales and marketing organization in the ...
... save children,s lives runs through December 8 in all 6,200 ... ... be,participating in the fourth year of the St. Jude Children,s Research,Hospital(R) ... December 8. As part of this national,campaign, CVS/pharmacy has joined with ...
... protein albumin suggests worsening coronary artery disease, study finds ... small amount of a protein called albumin in the ... their risk of cardiovascular death, say U.S. researchers. , ... age 50 and older, with stable coronary artery disease ...
Cached Medicine News:Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 2Health News:Crdentia Announces Promotion of Penny Kirsch to Vice President of Human Resources 3Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 2Health News:Imaging Diagnostic Systems to Present Laser Breast Imaging Clinical Results at the 2007 Radiological Society of North America Scientific Assembly 3Health News:Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 2Health News:CVS/pharmacy Launches St. Jude Thanks and Giving(R) Campaign in Stores Nationwide 3Health News:Urine Test Results Can Point to Heart Dangers 2
Flat Wire Stone Basket...
... Reichert MK1 Keratometer now utilizes ... consistent lighting, removing the need ... we didnt change are all ... made our Keratometer the worldwide ...
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Medicine Products: